Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.
As part of the agreement, Hims said it won’t compound GLP-1 medications like Zepbound in the future.
Original Source
Read the full article at Marketwatch →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.